HEALTH
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season – Merck.com
- U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season Merck.com
- FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca CNBC
- Merck Says It Wins US Approval for Shot to Prevent Infant RSV Bloomberg.com
- US FDA approves Merck’s RSV antibody for infants Reuters
- Merck’s RSV antibody treatment for infants is approved by FDA statnews.com
Source link
